Multiple Sclerosis

Research into Mesenchymal Stem Cells (MSCs) in Multiple Sclerosis (MS) is growing, with studies focusing on safety, feasibility, and potential neurological effects. Investigations explore whether MSCs may support repair processes in the central nervous system and modulate immune responses. 

Multiple Sclerosis is a chronic autoimmune disease in which the immune system attacks the protective myelin sheath around nerves. This leads to a wide range of symptoms, including fatigue, vision problems, muscle weakness, and difficulties with coordination. Current treatments may slow progression but do not reverse existing damage. 

MSC studies in MS remain exploratory, but early findings suggest possible roles in neuroprotection, inflammation control, and repair support. Continued research is essential for clarifying the potential of MSC-based approaches within the broader field of neurodegenerative disease treatment. 

Clinical Trials

Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis — Neil H Riordan, et al.


 

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study — Oscar Fernández, et al.


 

Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis — François Tremblay, et al.




Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis — Panayiota Petrou, et al.


 

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis — Dimitrios Karussis, et al.